All In Biotech

NDA 020597 · Upjohn

Xalatan

Latanoprost · Ophthalmic · Prostaglandin Analog

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jun 5, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

253

56 Phase 3, 9 recruiting

FAERS reports

50,175

27,826 serious, 3,136 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 15, 2024.

Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 20, 2002 Supplement 10 · Efficacy · priority review LabelLetter
  • Jun 5, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • XALATAN · LATANOPROST 0.005% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Latanoprost" as an intervention, any sponsor and status, largest first.

All 253 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure5,934
  • drug ineffective3,267
  • fatigue2,378
  • eye irritation2,178
  • headache1,837
  • intraocular pressure increased1,787
  • dyspnoea1,678
  • diarrhoea1,676
  • dizziness1,655
  • off label use1,647
  • eye pain1,642
  • death1,620

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004427
2005616
2006656
2007703
2008719
2009834
20102,052
20111,687
20121,971
20131,643
20141,876
20152,271
20162,722
20172,570
20182,846
20193,051
20208,873
20212,408
20222,369
20232,431
20242,481
20252,766
20262,203

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xalatan (Latanoprost)

2024 spending

$4.9M

Beneficiaries

2,384

10,322 claims

Per beneficiary

$2,049

$97.68 per unit

View as table
YearSpending
2020$8,408,259
2021$6,460,872
2022$5,673,411
2023$5,429,444
2024$4,884,115

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 637 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.